Monopar Therapeutics Files Proxy Materials
Ticker: MNPR · Form: DEFA14A · Filed: May 23, 2025 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | DEFA14A |
| Filed Date | May 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, regulatory, sec-filing
Related Tickers: MNPR
TL;DR
Monopar files proxy docs, no fee. Standard stuff.
AI Summary
Monopar Therapeutics Inc. filed a Definitive Additional Materials proxy statement on May 23, 2025. This filing relates to the company's proxy materials and does not involve a fee. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing is a routine regulatory submission for Monopar Therapeutics, providing shareholders with information related to upcoming corporate decisions or meetings.
Risk Assessment
Risk Level: low — This is a routine administrative filing with the SEC and does not contain new financial information or strategic decisions that would immediately impact the stock price.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- 0001437749-25-018329 (filing_id) — Accession Number
- 20250523 (date) — Filing Date
- DEFA14A (form_type) — Filing Type
FAQ
What type of filing is this?
This is a Definitive Additional Materials filing (DEFA14A) for Monopar Therapeutics Inc.
When was this filing submitted?
The filing was submitted on May 23, 2025.
Is there a fee associated with this filing?
No fee is required for this filing.
What is the company's fiscal year end?
Monopar Therapeutics Inc.'s fiscal year ends on December 31.
Where is Monopar Therapeutics Inc. incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware (DE).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 23, 2025 regarding Monopar Therapeutics (MNPR).